CSF1R and breast cancer: Anti-CSF-1R agents have been shown to be effective against recruitment of M2-like macrophages in breast cancer models, and anti-CSF1R inhibitors used in combination with paclitaxel decreased tumor growth and pulmonary metastasis (DeNardo et al., 2011).